Sionna Therapeutics, Inc.
SION
$42.18
-$0.59-1.38%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 77.53% | 117.63% | 128.13% | 113.24% | 104.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.56% | 30.22% | -14.93% | 94.00% | 49.53% |
| Operating Income | -50.56% | -30.22% | 14.93% | -94.00% | -49.53% |
| Income Before Tax | -62.47% | -28.98% | 20.29% | -111.27% | -39.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.47% | -28.98% | 20.29% | -111.27% | -39.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.47% | -28.98% | 20.29% | -111.27% | -39.12% |
| EBIT | -50.56% | -30.22% | 14.93% | -94.00% | -49.53% |
| EBITDA | -51.00% | -30.58% | 15.10% | -95.57% | -50.22% |
| EPS Basic | 3.81% | 86.45% | 91.92% | 84.87% | 83.87% |
| Normalized Basic EPS | 3.80% | 86.45% | 91.92% | 84.87% | 83.88% |
| EPS Diluted | 3.81% | 86.45% | 91.92% | 84.87% | 83.87% |
| Normalized Diluted EPS | 3.80% | 86.45% | 91.92% | 84.87% | 83.88% |
| Average Basic Shares Outstanding | 68.90% | 851.48% | 886.56% | 1,296.20% | 762.78% |
| Average Diluted Shares Outstanding | 68.90% | 851.48% | 886.56% | 1,296.20% | 762.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |